DXCM - Dexcom Inc

NASDAQ · Healthcare · Medical Devices

$75.37

Market Closed

End of day · Jun 12, 2026, 12:00 AM

Active

Resolved

Bull

Bear

About

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

https://www.dexcom.com

DXCM - Dexcom Inc

Healthcare

Looking at DXCM at 72.10, things feel a little shaky underneath the surface. You can see in the price action over the past year: DXCM has been tossed around from highs near 89 in late summer last year all the way down to lows around 59 in November. Even more recently, we saw a rebound to about 74 in late Jan, but it's still a choppy ride. That kind of volatility usually makes me pause before getting too excited. I lean bullish here, but not by a wide margin. My target is 81.00. The main thing that keeps me interested is that, despite all the swings, management has kept revenue growth pretty solid quarter to quarter. CGM (continuous glucose monitoring) adoption still looks like it's got room to run, and their tech has actual staying power at least compared to some of their competitors. Margins have also held up better than I expected, especially given all the supply chain headwinds last year. But there's a real risk that pricing pressure comes in harder than people anticipate, especially if insurers start pushing back. That's not something you can just ignore if payers squeeze them, it cuts right into their expansion case. Also worth flagging that the market seems skittish any time guidance gets tweaked, so no one should get too comfortable here. The next big move could come with the Q2 results. If they can show not just user growth but some stabilization in ASPs (average selling prices), I think the stock could get a bump. But I’m keeping a tight leash on this one if the business starts to wobble, I’d rather step aside than try to outsmart a falling knife.

Entry

$72.10

Above

$81.00

Aug 2, 2026

Karma

122 to 17261

Bullish

Open

Vote